Spyre Therapeutics's total assets for Q1 2025 were $569.78M, a decrease of -6.36% from the previous quarter. SYRE total liabilities were $87.17M for the fiscal quarter, a -3.87% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.